Leta i den här bloggen

söndag 12 oktober 2025

SVA tieto eläinten ihopahkurataudista, lumpy skin disease

 

ANMÄLNINGSPLIKTIG SJUKDOM EPIZOOTISJUKDOM

Lumpy skin disease orsakas av ett poxvirus och är närbesläktat med får- och getkoppor. Nötkreatur är det enda tamdjur som kan drabbas.

Förekomst;  Lumpy skin disease förekommer endemiskt i stora delar av Afrika, och har sedan flera år etablerat sig i Mellanöstern, Turkiet och Ryssland. Under 2015 rapporterades utbrott av Lumpy skin disease från Grekland, vilket var det första fallet av sjukdomen i EU. Året efter (2016) hade sjukdomen spridit sig till omkringliggande länder (Bulgarien, Nordmakedonien, Serbien, Montenegro, Albanien och Kosovo) och det rapporterades över 1 000 utbrott från dessa länder i sydöstra Europa. Sjukdomen bekämpades med hjälp av massvaccinering, och inga utbrott har rapporterats i de drabbade länderna sedan 2018. Under 2025 har utbrott rapporterats från Italien och Frankrike. Sjukdomen har aldrig påvisats i Sverige.
 
Symtom:Nötkreatur i alla åldrar insjuknar, men unga individer drabbas oftast hårdast. Den kliniska bilden hos nötkreatur varierar, alltifrån dödsfall till enstaka hudutslag utan övriga symtom. I fall med tydliga symtom ses knappformiga, runda hudutslag inom 48 timmar efter en inledande feberstegring. Utslagen kan uppkomma över hela kroppen, alltifrån några enstaka till flera hundra. Djuren blir allmänpåverkade, aptitlösa och får ödem på buk, ben och i dröglapp. Beroende på var utslagen sitter kan till exempel ögon- och nosflöde samt ökad salivering ses. Kopporna kan bli infekterade och bilda bölder. Normalt läker hudförändringarna först efter flera månader och ger bestående ärrbildning. Hudarna blir därför i praktiken värdelösa.
Smittämne; Sjukdomen orsakas av ett poxvirus (virussläktet 
 
Inkubationstid: Inkubationstiden är två till fyra veckor.
Smittvägar: Sjukdomen smittar främst med vektorer såsom flugor, myggor och andra bitande insekter. Direktsmitta mellan djur förekommer också.
Diagnos: Det snabbaste sättet att bekräfta diagnosen är påvisande av virusgenom i hudlesioner eller inre organ med PCR. Virusisolering och elektronmikroskopering av material från hudlesioner på det drabbade djuret är också säkra metoder för att påvisa virus.  I länder där smittan normalt inte förekommer kan påvisande av antikroppar också användas, men det går inte att skilja på antikroppar mot andra capripoxvirus, det vill säga de virus som orsakar får- och getkoppor. Serologi kan också användas i övervakningssyfte.
Om man misstänker sjukdomen: Lumpy skin disease lyder under

I Veterinära författningshandboken kan du läsa mer om den lagstiftning som gäller vid epizootisjukdomar.

Läs mer hos andra : Europeiska myndigheten för livsmedelssäkerhet (Efsa): Lumpy skin disease

https://www.woah.org/en/disease/lumpy-skin-disease/ 

 

Tuhkarokkovirus.

 https://pubmed.ncbi.nlm.nih.gov/41016799/

Review
. 2025;75(1):13-22.
doi: 10.2222/jsv.75.13. [Measles virus]
[Article in Japanese]
Affiliations
Abstract

Measles virus is the pathogen that causes measles and is highly infectious. Measles virus uses two molecules as viral receptors: signaling lymphocytic activation molecule, expressed on immune cells, and nectin-4, expressed on epithelial cells. Usage of these receptors is strongly associated with the pathogenesis of measles. Although it remains a leading cause of childhood mortality worldwide, measles elimination is being promoted by the availability of a highly effective live attenuated vaccines. Due to the elimination of measles in many countries, the circulating measles genotypes have been reduced to two, B3 and D8, in recent years. Therefore, in addition to genotyping using the conventional 450-nucleotide N gene region, new methods such as wholegenome sequencing and analysis of the M-F non-coding region are being tested for case association and outbreak tracking. Although measles virus is a single serotype, there are genomic differences among genotypes, including variations in B-cell and T-cell epitopes. However, current live attenuated vaccines remain sufficiently effective against all genotypes. On the other hand, the maintenance of protective immunity in vaccinees may become increasingly important, since vaccine-induced immunity tends to wane over time unlike the more durable immunity following natural infection.

 https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=11234

Measles morbillivirus
equivalent:
subacute sclerosing panencephalitis virus, SSPEV
Subacute sclerosing panencephalitis virus
Cell-associated subacute sclerosing panencephalitis
measles virus MV
rougeole virus
rubeola virus
subacute sclerose panencephalitis virus
Measles virus
measles

fredag 10 oktober 2025

POXVIRUKSET: LSDV ja muita POX-viruksia ...

 

Genome of Lumpy Skin Disease Virus


PMCID: PMC114441  PMID: 11435593

Abstract

Lumpy skin disease virus (LSDV), a member of the capripoxvirus genus of the Poxviridae, is the etiologic agent of an important disease of cattle in Africa. Here we report the genomic sequence of LSDV. The 151-kbp LSDV genome consists of a central coding region bounded by identical 2.4 kbp-inverted terminal repeats and contains 156 putative genes. Comparison of LSDV with chordopoxviruses of other genera reveals 146 conserved genes which encode proteins involved in transcription and mRNA biogenesis, nucleotide metabolism, DNA replication, protein processing, virion structure and assembly, and viral virulence and host range. In the central genomic region, LSDV genes share a high degree of colinearity and amino acid identity (average of 65%) with genes of other known mammalian poxviruses, particularly suipoxvirus, yatapoxvirus, and leporipoxviruses. In the terminal regions, colinearity is disrupted and poxvirus homologues are either absent or share a lower percentage of amino acid identity (average of 43%). Most of these differences involve genes and gene families with likely functions involving viral virulence and host range. Although LSDV resembles leporipoxviruses in gene content and organization, it also contains homologues of interleukin-10 (IL-10), IL-1 binding proteins, G protein-coupled CC chemokine receptor, and epidermal growth factor-like protein which are found in other poxvirus genera. These data show that although LSDV is closely related to other members of the Chordopoxvirinae, it contains a unique complement of genes responsible for viral host range and virulence.

Capripoxviruses (CaPVs) represent one of eight genera within the chordopoxvirus (ChPV) subfamily of the Poxviridae.

 The capripoxvirus genus is currently comprised of 
 lumpy skin disease virus (LSDV),  
 sheeppox virus (ShPV), and 
 goatpox virus (GPV). 
 
capra, goat, Bovidae 
sheep (Ovis), Bovidae
 Goat, capra, Bovidae 

These viruses are responsible for some of the most economically significant diseases of domestic ruminants in Africa and Asia (). CaPV infections are generally host specific and they have specific geographic distributions (, , ). CaPVs are, however, serologically indistinguishable from each other, able to induce heterologous cross-protection, and able in some instances to experimentally cross-infect (, , , ). Restriction fragment analysis and limited DNA sequence data support a close relationship between CaPVs (, , , ). The molecular basis of CaPV host range restriction and virulence remains to be elucidated.

LSD is a subacute to acute cattle disease in Africa. It is characterized by extensive cutaneous lesions and signs typical of generalized poxvirus diseases (, ). Transmission of LSD between cattle is inefficient, and arthropod-vectored transmission may be significant in epizootic outbreaks and in the spread of LSD into nonenzootic regions (, –, , , ).

 Attenuated LSDV strains and ShPV have been successfully used as LSD vaccines in enzootic and outbreak areas; however, vaccine failure and restrictions on the use of live virus vaccines create the need for a safe and effective, live attenuated vaccine (, , , ).

 Current molecular data on the LSDV genome consists of restriction endonuclease analysis, cross-hybridization studies, and limited transcriptional and DNA sequence analysis (, , , , , ). Given the economic significance of LSD, its potential for spread into nonenzootic regions, and the interest in developing more effective LSDV-based vaccines and expression vectors, we have sequenced and analyzed the genome of a pathogenic LSDV. These data provide the first view of a CaPV genome, and they define the gene complement that underlies LSDV virulence and host range.

--- 

LSDV contains 156 ORFs which have been annotated here as putative genes. These genes represent a 95% coding density and encode proteins of 53 to 2,025 amino acids (Fig. 1, Table 1). Similar to other poxviruses, many of the 41 putative early genes are members of gene families and/or putative host range genes, while the 46 genes containing the VV late promoter sequence (TAAATG) at the ATG codon () include many of the conserved virion-associated poxviral genes (Table 1).  

 Otan vain yhden proteiinin rrakenteen, siin on KELCH-proteiinin rakenne selvittettynä, propellit
 

ecName: Full=Protein C13

UniProtKB/Swiss-Prot: P32206.1

Identical Proteins FASTA Graphics 

LOCUS       VC13_SWPVK               500 aa            linear   VRL 05-FEB-2025
DEFINITION  RecName: Full=Protein C13.
ACCESSION   P32206
VERSION     P32206.1
DBSOURCE    UniProtKB: locus VC13_SWPVK, accession P32206;
            class: standard.
            created: Oct 1, 1993.
            sequence updated: Oct 1, 1993.
            annotation updated: Feb 5, 2025.
            xrefs: L22013.1, AAC37858.1
            xrefs (non-sequence databases): SMR:P32206, Gene3D:1.25.40.420,
            Gene3D:2.120.10.80, Gene3D:3.30.710.10, InterPro:IPR011705,
            InterPro:IPR000210, InterPro:IPR015915, InterPro:IPR006652,
            InterPro:IPR011333, PANTHER:PTHR24412, PANTHER:PTHR24412:SF489,
            Pfam:PF07707, Pfam:PF00651, Pfam:PF01344, SMART:SM00875,
            SMART:SM00225, SMART:SM00612, SUPFAM:SSF117281, SUPFAM:SSF54695,
            PROSITE:PS50097
KEYWORDS    Kelch repeat; Repeat.
SOURCE      Swinepox virus (STRAIN KASZA)
  ORGANISM  Swinepox virus (STRAIN KASZA)
            Viruses; Varidnaviria; Bamfordvirae; Nucleocytoviricota;
            Pokkesviricetes; Chitovirales; Poxviridae; Chordopoxvirinae;
            Suipoxvirus; Suipoxvirus swinepox.
REFERENCE   1  (residues 1 to 500)
  AUTHORS   Massung,R.F., Jayarama,V. and Moyer,R.W.
  TITLE     DNA sequence analysis of conserved and unique regions of swinepox
            virus: identification of genetic elements supporting phenotypic
            observations including a novel G protein-coupled receptor homologue
  JOURNAL   Virology 197 (2), 511-528 (1993)
   PUBMED   8249275
  REMARK    NUCLEOTIDE SEQUENCE.
COMMENT     [SIMILARITY] Belongs to the poxviruses Kelch family. {ECO:0000305}.
FEATURES             Location/Qualifiers
     source          1..500
                     /organism="Swinepox virus (STRAIN KASZA)"
                     /host="Sus scrofa (Pig)"
                     /db_xref="taxon:10277"
     gene            1..500
                     /locus_tag="C13L"
     Protein         1..500
                     /product="Protein C13"
                     /UniProtKB_evidence="Inferred from homology"
     Region          1..500
                     /region_name="Mature chain"
                     /note="Protein C13. /id=PRO_0000119169."
     Region          17..500
                     /region_name="PHA03098"
                     /note="kelch-like protein; Provisional"
                     /db_xref="CDD:222983"
     Region          27..89
                     /region_name="Domain"
                     /note="BTB.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU00037."
     Region          301..348
                     /region_name="Repetitive region"
                     /note="Kelch 1."
     Region          338..381
                     /region_name="KELCH repeat"
                     /note="KELCH repeat [structural motif]"
                     /db_xref="CDD:276965"
     Region          349..395
                     /region_name="Repetitive region"
                     /note="Kelch 2."
     Region          385..427
                     /region_name="KELCH repeat"
                     /note="KELCH repeat [structural motif]"
                     /db_xref="CDD:276965"
     Region          397..440
                     /region_name="Repetitive region"
                     /note="Kelch 3."
     Region          430..477
                     /region_name="KELCH repeat"
                     /note="KELCH repeat [structural motif]"
                     /db_xref="CDD:276965"
     Region          441..490
                     /region_name="Repetitive region"
                     /note="Kelch 4."
ORIGIN      
        1 mskqetyidy nyierlnavn lnrsydeeiv fimtvggvvk vkkellvsvs nyfklitknq
       61 sneitvsfqy esfldiikyi etgivtidld nvenifsisc skaidflkns cidfmskhit
      121 dstcvkiyki gfsngcfavy ndaiayirkr ftkietdill slslfdlrii lksgeldvss
      181 eddvllfiik wsrhkksnrr ksftlvtevl rynylsiygk ykltkwlarf gknnnvelne
      241 nelprisyqh rftnrrytmv tpssfsinml gnvsvknels iinsiaenhn pycgsvlmnd
      301 ilyliggink sldpvsdits vdtrsfielh tppllhprkc pgvaifknri yvvggigydg
      361 plktveswsp geqqwreevp llqprfnpci igtdndlyvv ggiseddkti eiysyeentw
      421 signamnysh fggciayhhg yiymigglsf idnihvftmv ekynphsnkw tvekslpfpr
      481 fnsslciied siaiigwiyy
//
  • LSDV eläinten virustauti genus Capripoxvirus,Chordopoxvirinae, Poxviridae Chitovirales, Pokkesviricetes , Nucleocytoviricota, Bamfordvirae Varidnaviria

     Tämä virus käyttää KELCH-proteiiniraknnetta  edukseen 

    Clinical signs:

    Clinical signs vary, with younger animals more severely affected.

    • Nodular skin lesions (lumps) on the animal’s body, muzzle, nose, head, neck, back, legs, scrotum, perineum, udder, eyelids, tail and mouth
    • Nodules can also develop internally, particularly in the respiratory and gastrointestinal tracts
    • Fever
    • Listlessness and reluctance to eat
    • Ocular and nasal discharge
    • Milk drop with weight loss
    Virology Taxonomy
    Realm Varidnaviria, 
    kingdom Bamfordvirae, 
    phylum Nucleocytoviricota,
     class Pokkesviricetes, 
    order Chitovirales, 
    family Poxviridae,
     subfamily Chordopoxvirinae,
     genus Capripoxvirus, 
    species Lumpy skin disease virus, LSDV
    Virion: LSDV virion displays a typical poxvirus morphology: brick-shaped virions (220-450 long × 140-260 wide × 140-260 nm thick). Virions consist of a lipoprotein surface membrane enclosing a biconcave core that contains the DNA genome. Two lateral bodies are present in the concave regions between the core and the membrane.
    Genome: The LSDV genome is a linear molecule of dsDNA,151,000 base pairs (bp) in length, with covalently-closed ends. The viral genome encodes 156 putative genes and is organized in a central region flanked by identical inverted terminal repeats of ~2,400 bp each.
    Lifecycle: Virus entry is mediated by fusion between viral and cellular membranes at the plasma membrane or following endocytosis. 
    The early phase of replication includes expression of proteins needed for replication of viral DNA and modulation of the host cellular functions and antiviral defences. 
    DNA replication and gene expression occur in the cytoplasm in ‘virus factories’ and is mediated by virus-encoded proteins. 
    The late phase of replication includes the expression of structural proteins involved in the multistage assembly of new virions. Virions are released by exocytosis or after cell lysis. 
     
     Abstract Lumpy Skin Disease Virus (LSDV) is a transboundary pathogen that affects cattle, causing significant economic losses, particularly in Africa and Asia. While the virus was originally endemic to sub-Saharan Africa, it has rapidly spread to Europe, the Middle East, and Asia, necessitating comprehensive genomic surveillance. 
    Despite LSDV's African origins, genomic data from West and Central Africa remain scarce, limiting insights into regional viral evolution and vaccine compatibility.
     In this study, molecular detection of LSDV was carried out on cattle samples from Nigeria, Cameroon, and Benin. However, comparative genomic analysis was performed using two near-complete LSDV genomes obtained from Cameroon.
     Phylogenetic evaluation revealed that LSDV strains from Nigeria and Cameroon cluster within the classical 1.2 lineage. Furthermore, the two sequences from this study cluster with the only publicly available sequence from West and Central Africa, supporting earlier findings of the presence of a West/Central African sub-lineage.
     Functional genomic analysis identified mutations in genes encoding ankyrin repeat Kelch-like proteins, and envelope proteins involved in immune evasion and viral virulence, raising concerns about vaccine effectiveness.
     Furthermore, the detection of LSDV in flesh flies (Sarcophaga spp.) underlines their potential role in virus transmission. 
    These findings highlight the importance of genomic monitoring and targeted surveillance.

    Keywords: Africa; Kelch-like proteins; Lumpy Skin Disease Virus (LSDV); SNP mutations; ankyrin repeat proteins; genomic analysis; phylogenetic analysis; poxviruses; vaccine efficacy; vector transmission.

     

    torsdag 9 oktober 2025

    Ruotsin Kansanterveysvirast seuraa Kongon ebolaepidemian kesättelyä

     https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/ebola-demokratiska-republiken-kongo-september-2025/

    Mitä Lancet kirjoittaa Kongon ebolapurkauksesta?

     

    CorrespondenceOnline firstOctober 03, 2025
    New Ebola virus disease outbreak in the Democratic Republic of the Congo: early response guidance

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01950-6/fulltext?rss=yes

     

    On Sept 4, 2025, in line with International Health Regulations (2005) requirements, the Minister of Health of the Democratic Republic of the Congo officially declared a new Ebola virus disease outbreak in Kasai province, affecting the health zone of Bulape. This new outbreak of Ebola virus disease has occurred in a fragile context, regionally and globally, as the Democratic Republic of the Congo is responding to an ongoing complex humanitarian situation, as well as outbreaks of cholera, mpox, and measles. The African region, as a whole, is adversely affected by the current global financial and geopolitical challenges. These external factors are likely to strain response measures in an already fragile situation, making decisive, rapid response by all actors—regional and international—of particular importance.
    Ebola virus disease represents a major public health risk due to the potential for international spread and high case-fatality rate, varying between 25% and 90%. Experience of the Ebola virus disease outbreak of 2014–16 in west Africa showed that, while the disease was initially assumed to occur only in isolated areas of central Africa, spread from rural to urban areas can occur, with substantial socioeconomic consequences. Both the experience of the Ebola virus disease outbreak in west Africa and the COVID-19 pandemic show how rapidly the spread of a disease can disrupt regional and global travel, trade, and other links.
    The Democratic Republic of the Congo has experienced 15 outbreaks of the disease in the past five decades. The largest outbreak occurred in August, 2018, in Nord Kivu and Ituri provinces (areas affected by armed conflicts), with 3740 cases reported including 2287 deaths—a case-fatality rate of 61%.
    The fourth and fifth Ebola virus disease outbreaks in the Democratic Republic of the Congo occurred in Mweka and Luebo in 2007 (264 cases reported) and in 2009 (32 cases reported). Kasai province is located in the south‑central part of the country, is made up of 18 health zones, and is bordered by seven provinces (Kwilu, Kwango, Sankuru, Tshuapa, Maindombe, Kasai Central, and Kasai Oriental) and one country (Angola) (appendix p 1).
    On Sept 4, 2025, the National Institute for Biomedical Research tested three samples from patients meeting the case definition of acute haemorrhagic fever, in Bulape health zone (which comprises five health areas), Kasai province, which were found to be positive for Ebola virus (Orthoebolavirus zairense). As of Sept 14, 2025, 35 confirmed cases have been reported, including 16 deaths (case-fatality rate 45·7%). Five health-care workers are among the confirmed cases. The index case is a 34-year-old pregnant woman who presented to the Bulape General Reference Hospital on Aug 20, 2025, with acute haemorrhagic syndrome, and died on Aug 25, 2025. Bulape is so far the only health zone affected. The neighbouring health zones of Mweka, Kakenge, and Mushenge reported suspected cases, but these all tested negative for Ebola virus.
    On Sept 2, 2025, following notification of suspected viral haemorrhagic fever cases, the Democratic Republic of the Congo Ministry of Health and WHO deployed the first rapid response team of experts, and shipped two tonnes of medical supplies and a mobile diagnostic laboratory, to Bulape health zone and its neighbouring health zone of Mweka in Kasai province. The first rapid response teams reached Mweka on Sept 4, 2025, and Bulape on Sept 5, 2025; these deployments were followed by those of other partners such as UNICEF, Médecins sans Frontières, and The Alliance for International Medical Action.
    On Sept 5, 2025, WHO graded the outbreak as a grade 3 public health emergency, involving the WHO headquarters and Regional Office for Africa in support to strengthen the country's outbreak response capacity. A summary of the timeline of the outbreak, as of Sept 5, 2025, is shown in the appendix (p 7).
    Vaccination of front-line health-care workers, contacts, and contacts of contacts started on Sept 13, 2025.
    The current confirmed Ebola virus disease outbreak is occurring in a province that shares borders with seven provinces and Angola. Tshikapa, the capital city of Kasai, is accessible from the national capital, Kinshasa, by air (two to three flights a week) and by 650 km of road. Mweka is 278 km from Tshikapa and accessible only by road. The distance between Mweka and Bulape is 27 km; poor road conditions make this a journey of around 12 h. However, despite limited accessibility, there is a high risk for the disease to spread outside Kasai province, especially to neighbouring provinces and Angola. Preventing cross-border spread requires urgent, rapid, and effective surveillance at points of entry to Kasai province, as well as preparedness measures in neighbouring areas.
    Kasai province has not experienced an Ebola virus disease outbreak for more than 15 years. The consequent lack of experience in managing Ebola virus disease outbreaks, coupled with a fragile health system, makes the province poorly prepared to respond effectively to this epidemic. This has been evidenced at the beginning of the outbreak by a shortage of personal protective equipment for case management and safe burials, as well as inadequate infection, prevention, and control measures.
    Ring vaccination for contacts, contacts of contacts, and front-line health-care workers has been one of the response strategies implemented in the last six Ebola virus disease outbreaks (in Equateur, Nord Kivu, and Ituri provinces) and has proven effective. Fortunately, the country had a stockpile of 2000 doses of the Ervebo vaccine, which was prepositioned in Kinshasa and quickly moved to Kasai.
    It is crucial that the Democratic Republic of the Congo Ministry of Health and international partners rapidly control this Ebola virus disease outbreak to prevent regional and international spread. Lessons learned from response to previous disease outbreaks have shown that the following are essential: (1) conduct a detailed outbreak investigation, including retrospective active case finding back to early July, focusing on health facilities and health areas with reported cases, as well as contact tracing in Bulape and neighbouring health zones; (2) strengthen infection, prevention, and control measures in all heath-care facilities, in communities, and at points of entry in Bulape and neighbouring health zones; (3) use experienced organisations, such as Médecins Sans Frontières and The Alliance for International Medical Action, for effective case management; (4) invest heavily in community engagement to counter misinformation and prevent community resistance, particularly against transfer of people with suspected infection to treatment centres and against safe and dignified burials; leverage the experience of the city of Beni during the tenth outbreak in setting up local committees in each health area that include community leaders to support outbreak response; (5) immediately start ring vaccination of contacts, contacts of contacts, and front-line health-care workers; (6) institute a data and modelling team to better inform decisions aimed at improving the effectiveness of outbreak response, as was done during the tenth outbreak; and (7) ensure that all response to the Ebola virus disease outbreak strengthens affected health-care systems to institutionalise outbreak preparedness and response measures.
    This Correspondence is intended to serve as an alert to the global community. We must not forget the lessons learned from decades of response to disease outbreaks and emergencies in the WHO African region, and from the COVID-19 pandemic, namely, the importance of high-level leadership, collaboration, and partnership.

    måndag 6 oktober 2025

    Mikä on BST2 geeni ja proteiini? (Recommended name: Bone marrow stromal antigen 2 ( Kr. 19p13.11)

     https://www.genecards.org/cgi-bin/carddisp.pl?gene=BST2&keywords=BST2

    Aliases for BST2 Gene

    • GeneCards Symbol: BST2 2
    • Bone Marrow Stromal Cell Antigen 2 2 3 5
    • Tetherin 2 3 4 5
    • BST-2 2 3 4 5
    • HM1.24 2 3 5
    • CD317 2 3 5
    • Bone Marrow Stromal Antigen 2 3 4
    • Antiviral Factor Tetherin 2 3
    • HM1.24 Antigen 3 4
    • CD317 Antigen 4
    • NPC-A-7 3

    External Ids for BST2 Gene

    NCBI Gene Summary for BST2 Gene

    • Bone marrow stromal cells are involved in the growth and development of B-cells. The specific function of the protein encoded by the bone marrow stromal cell antigen 2 is undetermined; however, this protein may play a role in pre-B-cell growth and in rheumatoid arthritis. [provided by RefSeq, Jul 2008]

    GeneCards Summary for BST2 Gene

    BST2 (Bone Marrow Stromal Cell Antigen 2) is a Protein Coding gene. Diseases associated with BST2 include Stomatitis and Colorado Tick Fever. Among its related pathways are Infectious disease and SARS-CoV-1-host interactions. Gene Ontology (GO) annotations related to this gene include RNA binding and obsolete signal transducer activity.

    UniProtKB/Swiss-Prot Summary for BST2 Gene

    IFN-induced antiviral host restriction factor which efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. The tethered virions can be internalized by endocytosis and subsequently degraded or they can remain on the cell surface. In either case, their spread as cell-free virions is restricted (PubMed:18200009, 18342597, 19036818, 19879838, 20019814, 20399176, 20419159, 20940320, 21529378, 22520941, 37922253). Its target viruses belong to diverse families, including retroviridae: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), prototype foamy virus (PFV), Mason-Pfizer monkey virus (MPMV), human T-cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae: lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis sarcoma-associated herpesvirus (KSHV), rhabdoviridae: vesicular stomatitis virus (VSV), orthomyxoviridae: influenza A virus, paramyxoviridae: nipah virus, and coronaviridae: SARS-CoV (PubMed:18200009, 18342597, 19179289, 19879838, 20399176, 20419159, 20686043, 20943977, 21529378, 21621240, 22520941, 26378163, 31199522). Can inhibit cell surface proteolytic activity of MMP14 causing decreased activation of MMP15 which results in inhibition of cell growth and migration (PubMed:22065321). Can stimulate signaling by LILRA4/ILT7 and consequently provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection (PubMed:19564354, 26172439). Plays a role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. Isoform 1 and isoform 2 are both effective viral restriction factors but have differing antiviral and signaling activities (PubMed:23028328, 26172439). Isoform 2 is resistant to HIV-1 Vpu-mediated degradation and restricts HIV-1 viral budding in the presence of Vpu (PubMed:23028328, 26172439). Isoform 1 acts as an activator of NF-kappa-B and this activity is inhibited by isoform 2 (PubMed:23028328). ( BST2_HUMAN,Q10589 ) 

     

     

    Lisätieto 6.10.-2025:   EBOV , proteiini GP .

    https://ictv.global/report/chapter/filoviridae/filoviridae/orthoebolavirus 

    GeneCards tieto:   Virion adsorption to orthoebolavirus susceptible cells via cellular attachment factors; determines orthoebolavirus cell and tissue tropism; induction of virus cell membrane fusion subsequent to endolysosomal binding to NPC1; inhibits innate immune response by interfering with BST2. GP1,2Δ triggers immune activation and increased vascular permeability 

     

     

    PubMed haku:  EBOV interaction with BST2? 5 vastausta: 

     

    Release of Immunomodulatory Ebola Virus Glycoprotein-Containing Microvesicles Is Suppressed by Tetherin in a Species-Specific Manner.
    Nehls J, Businger R, Hoffmann M, Brinkmann C, Fehrenbacher B, Schaller M, Maurer B, Schönfeld C, Kramer D, Hailfinger S, Pöhlmann S, Schindler M. Cell Rep. 2019 Feb 12;26(7):1841-1853.e6. doi: 10.1016/j.celrep.2019.01.065. PMID: 30759394 Free article.
    We characterized GP-mediated virosome formation and delineated the role of the antiviral factor tetherin (BST2, CD317) in this process. Residues in the EBOV-GP receptor-binding domain (RBD) promote GP-virosome secretion, while tetherin suppresses GP-virosomes by …
    A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
    González-Hernández M, Hoffmann M, Brinkmann C, Nehls J, Winkler M, Schindler M, Pöhlmann S. J Virol. 2018 Jun 13;92(13):e00403-18. doi: 10.1128/JVI.00403-18. Print 2018 Jul 1. PMID: 29669839 Free PMC article.
    Moreover, alteration of the GXXXA motif increased tetherin sensitivity of a replication-competent vesicular stomatitis virus (VSV) chimera encoding EBOV-GP. Although these results await confirmation with authentic EBOV, they indicate that a GXXXA motif in the TMD of …
    The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C, Nehlmeier I, Walendy-Gnirß K, Nehls J, González Hernández M, Hoffmann M, Qiu X, Takada A, Schindler M, Pöhlmann S. J Virol. 2016 Nov 28;90(24):11075-11086. doi: 10.1128/JVI.01563-16. Print 2016 Dec 15. PMID: 27707924 Free PMC article.
    The glycoprotein of Ebola virus (EBOV GP), a member of the family Filoviridae, facilitates viral entry into target cells. In addition, EBOV GP antagonizes the antiviral activity of the host cell protein tetherin, which may otherwise restrict EBOV release from …
    Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.
    Gustin JK, Bai Y, Moses AV, Douglas JL. J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S181-90. doi: 10.1093/infdis/jiv125. Epub 2015 Mar 27. PMID: 25821226 Free PMC article.
    Coincident with this discovery was the finding that the HIV Vpu protein down-regulates BST2 from the cell surface, thereby promoting viral release. Evidence suggests that the EBOV envelope glycoprotein (GP) also counteracts BST2, although the mechanism is unc …
    The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.
    Kühl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Stürzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pöhlmann S. J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S850-60. doi: 10.1093/infdis/jir378. PMID: 21987761 Free PMC article.
    The antiviral protein tetherin/BST2/CD317/HM1.24 restricts cellular egress of human immunodeficiency virus (HIV) and of particles mimicking the Ebola virus (EBOV), a hemorrhagic fever virus. ...Tetherin interacted with the GP2 subunit of EBOV-GP, which …